Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Cancer is associated with higher morbidity and mortality and is the second leading cause of
death in the US. Further, in some nations, cancer has overtaken heart disease as the …

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …

The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …

Reinvigoration of antitumor immunity remains an unmet challenge. Our retrospective
analyses revealed that cancer patients who took antihistamines during immunotherapy …

Single-cell RNA sequencing (scRNA-seq), a technology that analyzes transcriptomes of
complex tissues at single-cell levels, can identify differential gene expression and epigenetic …

Immune checkpoint blockade is able to induce durable responses across multiple types of
cancer, which has enabled the oncology community to begin to envision potentially curative …

Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-
tolerance and assist with immune response. In cancer, immune checkpoint pathways are …

Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been
reported in case series but have been underappreciated due to their recent emergence …

Co-inhibitory immune receptors can contribute to T cell dysfunction in patients with cancer,.
Blocking antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and …